Abstract

Diagnosis and treatment of myelofibrosis: a personal perspective

Author(s): Sabia Rashid, Deepti H Radia, Claire N Harrison

Myelofibrosis can arise de novo or following one of the other Philadelphianegative myeloproliferative neoplasms. The differential diagnosis may be challenging and can include other entities which may also express the JAK2 V617F mutation, such as chronic myelomonocytic leukemia and/or refractory anemia with ring sideroblasts. Traditionally a difficult disease to treat with only a small proportion of patients eligible for a curative bone marrow transplant, this field has recently changed radically with the introduction of JAK inihibitors, the first in class being ruxolitinib.